Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

[1]  J. McGill,et al.  Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study , 1995, Diabetes Care.

[2]  E. Ferrannini,et al.  Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production , 1994, Diabetes.

[3]  K. Kosaka,et al.  Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy , 1996, Diabetes Care.

[4]  P. Grant.  The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes , 1996, Diabetes Care.

[5]  R. Goldberg,et al.  A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents , 1996, Diabetes Care.

[6]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[7]  H. Beck-Nielsen,et al.  Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. , 1989, Acta endocrinologica.

[8]  L. Groop,et al.  Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM , 1992, Diabetes.

[9]  Hermann Ls.  Metformin: a review of its pharmacological properties and therapeutic use. , 1979 .

[10]  P. Bennett,et al.  Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr , 1987, Diabetes.

[11]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[12]  Williams Da,et al.  The comparison of several dose levels with a zero dose control. , 1972 .

[13]  Campbell Iw.  Metformin and the sulphonylureas: the comparative risk. , 1985 .

[14]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[15]  L. Groop,et al.  What Is the Benefit of Increasing the Sulfonylurea Dose? , 1993, Annals of Internal Medicine.

[16]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[17]  C. Sum,et al.  The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. , 1993, Metabolism: clinical and experimental.

[18]  A. Avogaro,et al.  Effect of Metformin on Insulin-Stimulated Glucose Turnover and Insulin Binding to Receptors in Type II Diabetes , 1987, Diabetes Care.

[19]  R. DeFronzo,et al.  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[20]  G. Reaven,et al.  Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. , 1992, The Journal of clinical endocrinology and metabolism.

[21]  Lawrence A Leiter,et al.  Cellular Mechanism of Action of Metformin , 1990, Diabetes Care.

[22]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.